A proteomics-based measure of cumulative stress outperforms traditional biomarkers

ProAL50, a novel proteomics-based biomarker, provides a more precise measurement of allostatic load—the cumulative physiological wear imposed by chronic stress—and demonstrably outperforms the heterogeneous clinical markers used in traditional approaches. Constructed from 50 circulating proteins using high-dimensional plasma proteomic data from the UK Biobank and externally validated in the CARDIA Study, ProAL50 exhibits consistently stronger associations with incident chronic diseases: cancers across all types, type 2 diabetes, ischemic heart disease, chronic lung disease, and chronic kidney disease, alongside all-cause and cause-specific mortality. Functional enrichment analyses show these proteins cluster within lipid metabolic and immune-inflammatory pathways, establishing a rigorous biological foundation. For longevity-focused readers, this represents a methodological inflection point: a scalable instrument that not only matches the construct validity of traditional measures but surpasses them materially in disease and mortality prediction, offering meaningful ground for population health research and personalized preventive medicine strategies.